ClinicalTrials.gg
CompletedNCT04873245QUESTUpdated Nov 6, 2026Results posted

Lifestyle Counseling and Medication for Adolescent Weight Management

A Phase 2 interventional study of Intensive Behavioral Program and Semaglutide and Behavioral Program in Obesity, Childhood, sponsored by University of Minnesota. Completed at 1 site in United States. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by University of Minnesota · Phase 2, Interventional, and Treatment

How we know · 5 judgments

Updated Nov 6, 2026Results postedEnrollment updated+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
121
Allocation
Randomized
Ages
12 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Pediatric Obesity by University of Minnesota — 1 open to participants now, 1 under way, none of them phase 3. Pediatric Obesity · University of Minnesota.

Enrollment
7th of 19
121 · median 80
Started
2022
with 4 others
Phase 2
3 of 20
none open now
Registered
14th of 20
by date

Among the 20 studies in Pediatric Obesity by University of Minnesota, this one is the 7th largest by enrollment of the 19 interventional ones that give a count, is one of 5 that started in 2022, is one of 3 in phase 2, and was the 14th registered.

Pediatric Obesity

1,132 studies on the registry are indexed under Pediatric Obesity; 183 are open to participants now.

Browse Pediatric Obesity studies →

Open to participants now

1 of the 20 studies in Pediatric Obesity by University of Minnesota is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 119 Pediatric Obesity studies recruiting now, 16 (13%) set no upper age limit and 101 (85%) stop at 75 or younger; 110 take children under 18; 67 take healthy volunteers.

This study: 12 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Pediatric Obesity by University of Minnesota, or all of them as a file.
02

Study summary

The prevalence of adolescent severe obesity is at an all-time high in the United States and the refractory nature of this disease has led to a serious and challenging conundrum in terms of how to provide effective, safe, scalable, and durable treatments without placing undue strain on the healthcare system. Clinical practice guidelines recommend behavioral interventions as the primary strategy for all ages and classes of obesity - moderate to severe. In 2017, the U.S. Preventive Services Task Force (USPSTF) released updated screening recommendations concluding that comprehensive, intensive behavioral interventions with a total of ≥26 contact hours over a period of 2-12 months resulted in weight loss in youth with obesity, with ≥52 contact hours leading to even greater weight loss and improvements in some cardiometabolic risk factors.

However, the practicality of delivering these types of intensive behavioral services to the millions of youth with severe obesity in the U.S. is debatable not only because of the treatment-resistant nature of severe obesity, but also due to the time-commitment, acceptability, and sustainability of this approach for adolescent patients and their families along with the extensive resources required to provide these interventions. Indeed, fewer than 50% of pediatric patients referred for weight management services enroll in treatment, and high attrition rates of up to 50% have been reported in behavioral-based clinical trials and in the clinical setting. Moreover, adherence to behavioral counseling significantly diminishes over time, which too often erodes early weight loss success and ultimately derails durability. The reality of what most patients/families are able to do and the unique physiological and psychosocial features of severe obesity in adolescence do not seem to align well with the degree of intensity of behavioral interventions shown to be effective by the USPSTF. Therefore, a critical appraisal of the feasibility, effectiveness, and sustainability of the USPSTF recommendations among adolescents with severe obesity is warranted.

While behavior change is an indispensable component of any effective weight loss approach, adjunctive strategies such as pharmacotherapy may enhance outcomes in adolescents with severe obesity. Many maladaptive behaviors attributed to obesity are driven by underlying biological forces, such as increased appetite and food palatability, that are largely beyond the control of the individual. Pharmacotherapy can help facilitate behavior change by disrupting core pathophysiological processes and restoring homeostasis to the energy regulatory system, therein enabling individuals to sustain healthy behavior change. Though under-explored as a treatment for adolescent obesity, pharmacotherapy along with relatively low-intensity behavioral counseling (\<26 contact hours) represents a potentially effective, durable, and safe treatment strategy. This approach may be more practical and feasible to implement on a broad scale, be preferred by patients/families, utilize fewer healthcare resources, and cost less to deliver compared to comprehensive, intensive behavioral interventions.

Read the detailed description

This is a two-arm, randomized clinical trial in adolescents with severe obesity evaluating 52 weeks of intensive behavioral counseling, aligned with USPSTF recommendations (52 contact hours), vs. 52 weeks of medical management with semaglutide (glucagon-like peptide-1 receptor agonist) plus relatively low-intensity behavioral counseling (12 contact hours).

03

Conditions studied

  • Obesity, Childhood

Browse trials for

04

Who can participate

Ages eligible
12 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Obesity ( (BMI) >/= 95th percentile or BMI >/= 30 kg/m2)
  • Age 12 to \< 18 years old and Tanner stage >1

Exclusion criteria

Exclusion Criteria:

  • Diabetes (type 1 or 2)
  • Current or recent (\< 6 months prior to enrollment) use of anti-obesity medication(s) defined as orlistat, phentermine, topiramate, combination phentermine/topiramate, liraglutide (or other GLP-1RA) and/or combination naltrexone/bupropion (monotherapy use of naltrexone or bupropion is not an exclusion)
  • Previous bariatric surgery
  • Any history of treatment with growth hormone
  • Medically-documented history of bulimia nervosa
  • Any history of schizophrenia, psychosis, mania, chemical dependency
  • Unstable depression requiring hospitalization within the previous 6 month
  • Any history of suicide attempt
  • History of suicidal ideation or self-harm within the previous 30 days as determined at screening by a PHQ-9 score >/= 15 or Suicidal ideation of type 4 or 5 on the C-SSRS
  • Current pregnancy or plans to become pregnant
  • or AST >/= 5 times the
  • Creatinine > 1.2 mg/dL
  • Uncontrolled hypertension as determined by the local medical monitor
  • Diagnosed and medically-documented monogenic obesity
  • Medically-documented history of cholelithiasis
  • Untreated thyroid disorder
  • Medically documented history of pancreatitis
  • Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2
  • heart disease as determined by the local medical monitor
  • Personal history of malignant neoplasms within the past five years
  • to any component of semaglutide
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
121 participants (actual)

Study arms

  • Active comparator
    Intensive Behavioral Program Arm

    Participants randomized to this arm of the study will receive intensive behavioral therapy. Participants will receive 52 weekly sessions (50% in person and 50% virtual).

    Behavioral: Intensive Behavioral Program

  • Active comparator
    Medication Arm

    Participants randomized to this arm of the study will receive semaglutide and will receive behavioral therapy. Behavioral therapy will consist of 12 monthly sessions (50% in person and 50% virtual).

    Drug: Semaglutide and Behavioral Program

Interventions

  • BehavioralIntensive Behavioral Program

    Participants randomized to this group will receive intensive behavioral therapy.

  • DrugSemaglutide and Behavioral Program

    Participants randomized to this group will receive semaglutide and behavioral therapy.

This study also gives SemaglutideStudies of SemaglutideSemaglutide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Percent Change in Body Mass Index

    The percent change in body mass index (BMI) from Baseline to Week 56 will be calculated. BMI is defined as a person's weight in kilograms divided by the square of height in meters.

    Time frame: Randomization to Week 56

07

Results

Posted Nov 6, 2026

Participant flow

Recruitment letters and flyers were utilized for this project.

Participant flow — Overall Study
MilestoneIntensive Behavioral Program ArmMedication Arm
Started6160
Completed5058
Not completed112
Withdrew: Adverse event10
Withdrew: Lost to follow-up21
Withdrew: Physician decision10
Withdrew: Withdrawal by subject71

Outcome measures

PrimaryPercent Change in Body Mass Index

The percent change in body mass index (BMI) from Baseline to Week 56 will be calculated. BMI is defined as a person's weight in kilograms divided by the square of height in meters.

Time frame:
Randomization to Week 56
Reported as:
Mean · % change in body mass index (BMI)
Percent Change in Body Mass Index
% change in body mass index (BMI)Intensive Behavioral Program ArmMedication Arm
Percent Change in Body Mass Index-1.8 ± 34-22.3 ± 34

Adverse events

Collected over All cause mortality, serious adverse event and adverse event information was collected from the time of consent until Week 56.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Intensive Behavioral Program Arm0/61 (0%)2/61 (3.3%)34/61 (55.7%)
Medication Arm0/60 (0%)1/60 (1.7%)59/60 (98.3%)
Most frequent serious events
Most frequent serious events
EventIntensive Behavioral Program ArmMedication Arm
AppendicitisGastrointestinal disorders0/611/60
Chemical Dependency TreatmentPsychiatric disorders1/610/60
Suicidal Ideation hospitalizationPsychiatric disorders1/610/60
Most frequent other events
Showing 10 of 16
Most frequent other events
EventIntensive Behavioral Program ArmMedication Arm
NauseaGastrointestinal disorders15/6140/60
Abdominal painGastrointestinal disorders16/6133/60
VomitingGastrointestinal disorders11/6132/60
DiarrheaGastrointestinal disorders10/6130/60
Abdominal DistensionGastrointestinal disorders4/6118/60
ConstipationGastrointestinal disorders6/6115/60
COVID InfectionInfections and infestations3/618/60
DizzinessNervous system disorders0/618/60
HeartburnGastrointestinal disorders6/617/60
NasopharyngitisInfections and infestations5/616/60

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Intensive Behavioral Program ArmMedication ArmTotal
<=18 years6160121
Between 18 and 65 years000
>=65 years000
Sex: Female, Male
Sex: Female, Male(Participants)Intensive Behavioral Program ArmMedication ArmTotal
Female373875
Male242246
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Intensive Behavioral Program ArmMedication ArmTotal
Hispanic or Latino8311
Not Hispanic or Latino5357110
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Intensive Behavioral Program ArmMedication ArmTotal
American Indian or Alaska Native112
Asian404
Native Hawaiian or Other Pacific Islander000
Black or African American11920
White404383
More than one race4711
Unknown or Not Reported101
Region of Enrollment
Region of Enrollment(participants)Intensive Behavioral Program ArmMedication ArmTotal
United States6160121
08

Study locations

1 site
  • University of Minnesota, Delaware Clinical Research Unit
    Minneapolis, Minnesota 55414, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — To be determined

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Sharing will be available 10 years after the trial has been concluded.

Access criteria: Individuals should contact the study PI for information.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2022 to primary completion in Jun 2026, 51 months.

Results were first posted in Nov 2026, 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2021
First posted
May 5, 2021
StartActual
Mar 15, 2022
Primary completionActual
Jun 29, 2026
CompletionActual
Jun 30, 2026
Results first posted
Nov 6, 2026
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 6, 2026
Enrollment
120→121
Nov 6, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedPercent Change in body mass indexBody Mass IndexTime frame: 56 weeks → Randomization to Week 56
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Results posted
    Enrollment 120→121
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedPercent Change in body mass indexBody Mass IndexTime frame: 56 weeks → Randomization to Week 56
    + 2 other changes: index terms and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04873245
Responsible party
Sponsor
First posted
May 5, 2021
Start date
Mar 15, 2022
Primary completion
Jun 29, 2026
Completion
Jun 30, 2026
Results posted
Nov 6, 2026
Last update
Nov 6, 2026

Study contacts

Aaron Kelly, PhD
principal investigator · University of Minnesota

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Semaglutide

Start the discussion